Teva Releases Innovation and Social Responsibility Highlights
25 Janvier 2016 - 2:30PM
Business Wire
Leading Global Pharmaceutical Company Recaps
Latest Milestones, from Bolstering Digital Healthcare Start-Ups to
Creating Tailored Treatments
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA)
released its Corporate Social Responsibility Highlights today. In
one year, Teva—the world's largest generic medicines maker and
recognized leader in specialty pharmaceuticals—launched more than
315 new generic medicines to more than 200 million patients, in
over 60 countries. Additionally, Teva is on target to launch over
1000 new generic medicines in 2016 and nearly 1500 new generic
medicines in 2017 as well as 27 new specialty products by 2019.
“We remain committed to ensuring that our medicines are
available and adapted to serve global and changing healthcare
needs,” said Teva President and CEO Erez Vigodman. “The highlights
released today demonstrate our evolution over the last few years as
we make healthcare accessible for billions of people around the
world and seek to reduce the burden on national economies and
investing in development to bring new therapeutic options to
patients.”
Teva’s work in decreasing generic prescription drug prices in
the U.S., saving billions for the UK National Health Service,
lowering greenhouse gas emissions and other recent insights into
the company’s social responsibility and innovation efforts can be
found in “Innovating for Better Health: Teva Global Corporate
Social Responsibility Highlights.”
Highlights include:
- Creating the next generation of
health startups. In January 2015, Teva, in collaboration with
Phillips Healthcare, launched Sanara Ventures. It is
the first partnership of its kind in Israel. The venture capital
incubator committed to investing approximately $26 million to
support 40-50 early-stage digital healthcare and medical device
companies in the next eight years. To date, out of 400
applications, four companies have received funding, with two
receiving full licensure in the digital health and respiratory
space.
- Enhancing patient treatment
methods. Teva scientists are playing a unique role in
developing innovative therapies by taking already known molecules
and repurposing and transforming them for better efficacy, safety
and improved patient compliance. Current new therapies are in
advanced stages of development and include a long-lasting,
ready-to-use treatment for schizophrenia patients.
- Personalized medicine.
Teva’s pharmacogenomics research in Israel is working to identify
specific genetic modifications among similar communities. The
potential exists to develop targeted treatments that can prevent
serious diseases in populations with similar genetic markers.
- Supporting women in leadership
positions around the globe. At Teva, 49 percent of total
management at all levels, and 35 percent of executives and
senior management are women. Research from 2015 on business
diversity shows that around the world just 22 percent of senior
roles are held by women, compared to 19 percent in 2004.
These milestones align with the announcement of Teva’s Target
Zero vision to achieve zero incidents, zero injuries and zero
releases into the environment. As part of this vision, Teva pledged
to reduce energy consumption by 20 percent and reduce greenhouse
gas emissions 15 percent by 2020. Between 2012 and 2014, Teva cut
greenhouse gas emissions by six percent and reduced water usage by
17 percent in 2014 alone.
Each year, since 2011, Teva has responded to the climate change
information survey by the Carbon Disclosure Project, most recently
scoring a 96B out of a highest possible score of 100A.
“These highlights demonstrate Teva’s continued commitment to
offer real value to patients and healthcare systems around the
globe,” said Iris Beck-Codner, Group Executive Vice President,
Corporate Marketing Excellence and Communications. "The report also
highlights our sustained efforts to preserve the environment, as
well as our steadfast commitment to ensure that Teva employees
achieve their fullest potential in a healthy work environment. As a
whole, it reflects the progress we've made, our vision for the
future and our belief that the global healthcare industry must play
an increasingly integral role in creating accessible, innovative
and sustainable solutions for people everywhere.”
To learn more about Teva’s Corporate Social Responsibility
efforts, please visit:
http://www.tevapharm.com/corporate_responsibility/.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly
every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our innovative
products, especially Copaxone® (including competition from
orally-administered alternatives, as well as from potential
purported generic equivalents) and our ability to migrate users to
our 40 mg/mL version; the possibility of material fines, penalties
and other sanctions and other adverse consequences arising out of
our ongoing FCPA investigations and related matters; our ability to
achieve expected results from the research and development efforts
invested in our pipeline of specialty and other products; our
ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to
identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate
acquisitions; the extent to which any manufacturing or quality
control problems damage our reputation for quality production and
require costly remediation; increased government scrutiny in both
the U.S. and Europe of our patent settlement agreements; our
exposure to currency fluctuations and restrictions as well as
credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property
rights of our specialty medicines; the effects of reforms in
healthcare regulation and pharmaceutical pricing, reimbursement and
coverage; governmental investigations into sales and marketing
practices, particularly for our specialty pharmaceutical products;
adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with
internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of
our data security; competition for our generic products, both from
other pharmaceutical companies and as a result of increased
governmental pricing pressures; competition for our specialty
pharmaceutical businesses from companies with greater resources and
capabilities; the impact of continuing consolidation of our
distributors and customers; decreased opportunities to obtain U.S.
market exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that
are not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial
talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges
relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting
reliance on access to the capital markets; potentially significant
increases in tax liabilities; the effect on our overall effective
tax rate of the termination or expiration of governmental programs
or tax benefits, or of a change in our business; variations in
patent laws that may adversely affect our ability to manufacture
our products in the most efficient manner; environmental risks; and
other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2014 and in our other filings with
the U.S. Securities and Exchange Commission. Forward-looking
statements speak only as of the date on which they are made and we
assume no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160125005390/en/
Teva Pharmaceutical Industries Ltd.IR Contacts:United
StatesKevin C. Mannix, (215) 591-8912Ran Meir, (215)
591-3033orIsraelTomer Amitai, 972 (3) 926-7656orPR
Contacts:IsraelIris Beck Codner, 972 (3) 926-7687orUnited
StatesDenise Bradley, (215) 591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024